Stefan Irion

Stefan Irion, MD, leads the Research organization at BlueRock Therapeutics. Since joining BlueRock in 2017, Stefan has taken on a number of roles in support of BlueRock’s scientific goals; developing CNS strategy, advancing the DA01 program through IND clearance, advancing multiple neurology pipeline candidates to the next stage of development to building, and expanding a cross-site and cross-functional research team. Prior to BlueRock, Stefan was part of the leadership team at Memorial Sloan Kettering that developed MSK-DA01, the current lead program at BlueRock. Stefan worked as a Senior Scientist at iPierian developing iPSCs prior to joining MSK. Stefan received his MD from the University of Tuebingen and did Postdoctoral Fellowship work at both Mount Sinai School of Medicine in New York and the University Health Network in Toronto.